R&D channel feed – Endpoints News

R&D channel feed

Discontinuation day: Third Harmonic’s only drug fails safety study as BioCryst culls pipeline after ASH

3 years ago

Enlaza launches with $61M, aims to take covalency into protein drugs

3 years ago

Sio fails to find buyer, ending 'vant journey in liquidation

3 years ago

With new CEO, Passage Bio gives early look at first six patients in GM1 gangliosidosis gene therapy trial

3 years ago

Avidity touts early data, showing positive effect on progressive muscular disease while under partial FDA hold

3 years ago

Icosavax pushes forward with an RSV candidate after Covid-19 vaccine flop

3 years ago

Targeted radiotherapy biotech out of Longitude Capital raises a fresh $75M

3 years ago

Kymera and Sanofi move ahead with skin drug after promising PhI data

3 years ago

Pfizer projects mRNA vaccine sales will hover around $15B by 2030

3 years ago

Wave Life Sciences to receive $170M upfront in new partnership with GSK to develop a large number of candidates

3 years ago

Researchers call for using more than surrogate outcomes to approve new antibiotics

3 years ago

#ASH22: Novartis PNH drug tops AstraZeneca with what's described as 'practice-changing' potential

3 years ago

#ASH22: BeiGene's BTK inhibitor shows superiority to AbbVie, J&J blockbuster in PFS

3 years ago

Chris Garabedian's Xontogeny shepherds two more companies through $60M Series A rounds

3 years ago

Updated: Moderna claims cancer vaccine success in trial of mRNA shot with Merck

3 years ago

Updated: FDA approves Mirati's KRAS drug in non-small cell lung cancer

3 years ago

#ASH22: Regeneron claims it has set a 'new benchmark' in follicular lymphoma

3 years ago

ImmunityBio looks to pull in $157M from founder Patrick Soon-Shiong and another investor

3 years ago

Black Diamond spins out antibody work into new biotech with $30M from Versant, NEA

3 years ago

Vertex, Moderna prepare to take their inhaled mRNA cystic fibrosis drug into the clinic

3 years ago

#ASH22: ALX Oncology reports complete response with anti-CD47 candidate in combo trial

3 years ago

#ASH22: Lilly’s Loxo rounds out the PhI/II data for lymphoma drug under FDA review

3 years ago

#ASH22: Cogent touts data on small subset of rare disease patients in bid to compete with Blueprint

3 years ago

GSK chief Emma Walmsley picks out a trim new global HQ in downsizing move

3 years ago

First page Previous page 106 107 108109110 111 112 Next page Last page